文章基本信息

标题：Postoperative nausea and vomitting – prevention and treatment
本地全文：下载
作者：Ewa Piasek ; Olga Padała ; Adrianna Krupa 等
期刊名称：Journal of Education, Health and Sport
电子版ISSN：2391-8306
出版年度：2019
卷号：9
期号：9
页码：790-796
DOI：10.5281/zenodo.3460317
语种：English
出版社：Kazimierz Wielki University
摘要：Postoperative nausea and vomiting is a complication, which occurs in 30% of patients undergoing anesthesia and surgery. Moreover, large number of risk factors may result in PONV in up to 80% patients. Risk factors can be divided into patient-dependent and anesthesia dependent. Nowadays, prophylaxis and treatment of PONV is multimodal. Using agents affecting different types of receptors, results in decreasing frequency of postoperative nausea and vomiting. Dexamethasone is a corticosteroid used for prevention in patients with intermediate and high risk of PONV. Ondansetron is 5HT3 receptor antagonist. Ondansetron is more effective for post-operative vomiting than nausea. Side effects include: headaches, dizziness, diarrhea and constipation, prolonged QT interval and cardiac arrythmias. Aprepitant, tachykinin 1 (NK1) receptor antagonist is used in prevention of PONV. This antiemetic drug is recommended for patients with high risk of PONV and for whom PONV may result in serious complications. Scopolamine is a selective competitive antagonist of muscarinic cholinergic receptor. Besides sedative and amnestic effect, scopolamine has antiemetic effect, which is used for treatment of PONV. Postoperative nausea and vomiting may result in dehydration, electrolyte imbalance, suture disruption and bleeding, aspiration of gastric content and pneumonia. Complications mentioned above result in longer hospital stay and increased medical costs. Assessment of risk factor, avoiding emetogenic anesthetics and analgesics, multimodal prophylaxis and treatment is the best solution to decrease risk of PONV.
关键词：Postoperative nausea and vomiting is a complication, which occurs in 30% of patients undergoing anesthesia and surgery. Moreover, large number of risk factors may result in PONV in up to 80% patients. Risk factors can be divided into patient-dependent and anesthesia dependent. Nowadays, prophylaxis and treatment of PONV is multimodal. Using agents affecting different types of receptors, results in decreasing frequency of postoperative nausea and vomiting. Dexamethasone is a corticosteroid used for prevention in patients with intermediate and high risk of PONV. Ondansetron is 5HT3 receptor antagonist. Ondansetron is more effective for post-operative vomiting than nausea. Side effects include: headaches, dizziness, diarrhea and constipation, prolonged QT interval and cardiac arrythmias. Aprepitant, tachykinin 1 (NK1) receptor antagonist is used in prevention of PONV. This antiemetic drug is recommended for patients with high risk of PONV and for whom PONV may result in serious complications. Scopolamine is a selective competitive antagonist of muscarinic cholinergic receptor. Besides sedative and amnestic effect, scopolamine has antiemetic effect, which is used for treatment of PONV. Postoperative nausea and vomiting may result in dehydration, electrolyte imbalance, suture disruption and bleeding, aspiration of gastric content and pneumonia. Complications mentioned above result in longer hospital stay and increased medical costs. Assessment of risk factor, avoiding emetogenic anesthetics and analgesics, multimodal prophylaxis and treatment is the best solution to decrease risk of PONV.